Remoxipride — A selective dopamine D2 antagonist in the treatment of acute schizophrenia: a Canadian multicentre clinical trial

Authors :: A.G. Awad
P. Sandor
R. Ancill
P. Max
D. Bakish
Guy Chouinard
N.P.V. Nair
J. MacClure
P. Beaudry
Y.D. Lapierre
Barry Jones
R. Manchanda
B. Saxena
Source :: Schizophrenia Research. 3:45
Publication Year :: 1990
Publisher :: Elsevier BV, 1990.

Subjects :: medicine.medical_specialty
Acute schizophrenia
business.industry
Antagonist
Pharmacology
Clinical trial
Psychiatry and Mental health
Dopamine receptor D2
medicine
Remoxipride
Psychiatry
business
Biological Psychiatry
medicine.drug

Tools